Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the issued share capital as of March 31, 2010:
- Total issued Ordinary shares: 5,666,441,207 (25p each).
- Treasury shares held: 474,194,158.
- Total voting rights: 5,192,247,049.
No comparative data for prior periods is included in this specific text to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,192,247,049) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (474,194,158) to calculate the free float accurately.
- Check subsequent filings for financial performance data, as this 6-K does not contain earnings or cash flow information.